Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection

PHASE3CompletedINTERVENTIONAL

Enrollment

246

Participants

Timeline

Start Date

February 11, 2021

Primary Completion Date

December 20, 2021

Study Completion Date

December 22, 2021

Conditions

Vaccine Adverse ReactionSeroconversion

Interventions

BIOLOGICAL

SARS-Cov-2 neutralizing antibody titer

Quantitation of SARS-Cov-2 antibody titer at baseline after each dose of the vaccine

Trial Locations (1)

Zagazig University Faculty of Medicine, Zagazig

All Listed Sponsors

lead

Zagazig University

OTHER_GOV

NCT04756271 - Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection | Biotech Hunter | Biotech Hunter